{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:50:06Z","timestamp":1778601006301,"version":"3.51.4"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Hochschule Hannover (MHH)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Rising bacterial resistance is a global threat, causing rising financial burdens on healthcare systems and endangering effective treatment of bacterial infections. To ensure the efficacy of antibacterial drugs, it is essential to identify the most dangerous pathogens and vulnerable antibacterial drugs. Previous research by our group suggested irrational outpatient prescribing practices in Germany, supporting a growing bacterial resistance. This study analyses developments and characteristics for the ten most prescribed antibacterial drugs in Germany from 2008 to 2022. Conclusions are based on the development of bacterial resistance levels and an analysis of correlations between pathogens. We identified cefuroxime axetil, sulfamethoxazole-trimethoprim and nitrofurantoin as the most problematic drugs. Particularly problematic pathogens include <jats:italic>E. faecalis<\/jats:italic>, <jats:italic>E. faecium<\/jats:italic>, <jats:italic>K. pneumoniae<\/jats:italic>, and <jats:italic>P. mirabilis<\/jats:italic>. Besides increasing bacterial resistance, they are characterised by a high proportion of significant positive correlations, indicating a high potential for mutually reinforcing resistance development. Alarmingly, most of the antibacterial drugs analysed showed a growing resistance to at least one of the analysed pathogens. In most cases, the best treatment option is threatened by increasing bacterial resistance. We also identified several differences between current bacterial resistance data and therapeutic guidelines. In aggregate, our findings support irrational prescribing behaviour and underscore the urgent need for improved prescribing practices to counter rising bacterial resistance in Germany. Moreover, therapeutic guidelines for bacterial infections, the \u201choly grail\u201d of pharmacotherapy, must be updated more frequently.<\/jats:p>","DOI":"10.1007\/s00210-024-03533-6","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T01:02:12Z","timestamp":1729645332000},"page":"4219-4236","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Development of bacterial resistance in Germany from 2008 to 2022 \u2014 major culprit pathogens, antibacterial drugs, and prescribing practices"],"prefix":"10.1007","volume":"398","author":[{"given":"Lilly Josephine","family":"Bindel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Seifert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"3533_CR1","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2016) S2k-Leitlinie: Infektionen mit Chlamydia trachomatis. AWMF-Register-Nr. 059-005. Last updated: August 2016. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/059-005. Last accessed: 5 October 2024"},{"key":"3533_CR2","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2017) Interdisziplin\u00e4re S3 Leitlinie Epidemiologie, Diagnostik, Therapie, Pr\u00e4vention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten. Langversion. Aktualisierung 04\/2017. AWMF-Register-Nr. 043\/044. Version 1.1-2. https:\/\/register.awmf.org\/assets\/guidelines\/043-044l_S3_Harnwegsinfektionen_2017-05.pdf. Last Accessed: 19 September 2024"},{"key":"3533_CR3","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2018) S2k-Leitlinie: Kalkulierte parenterale Initialtherapie bakterieller Erkrankungen bei Erwachsenen \u2013 Update 2018. AWMF-Register-Nr. 082-006. Last updated: Juli 2018. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/082-006. Last accessed: 5 October 2024"},{"key":"3533_CR4","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2019b) S2k-Leitlinie: Sexuell \u00fcbertragbare Infektionen \u2013 Beratung, Diagnostik und Therapie. AWMF-Register-Nr. 059-006. Last updated: September 2019. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/059-006. Last accessed: 5 October 2024\u200b"},{"key":"3533_CR5","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2019a) S2k-Leitlinie Antibiotikatherapie der Infektionen an Kopf und Hals. AWMF-Register-Nr. 017-066. Last updated: November 2019. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/017-066. Last accessed: 5 October 2024"},{"key":"3533_CR6","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2020) S3-Leitlinie: Sepsis \u2013 Pr\u00e4vention, Diagnose, Therapie und Nachsorge. AWMF-Register-Nr. 079-001. Last updated: M\u00e4rz 2020. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/079-001. Last accessed: 5 October 2024\u200b"},{"key":"3533_CR7","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2023) S3-Leitlinie: Lungenerkrankung bei Mukoviszidose \u2013 Pseudomonas aeruginosa. AWMF-Register-Nr. 026-022. Last updated: Februar 2023. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/026-022. Last accessed: 5 October 2024"},{"key":"3533_CR8","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2024a) S3-Leitlinie: Epidemiologie, Diagnostik, Therapie, Pr\u00e4vention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei Erwachsenen \u2013 Aktualisierung 2024. Langversion 3.0. AWMF-Register-Nr. 043-044. Last updated: April 2024. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/043-044. Last accessed: 19 September 2024"},{"key":"3533_CR9","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (2024b) S2k-Leitlinie: Management der ambulant erworbenen Pneumonie bei Kindern und Jugendlichen. AWMF-Register-Nr. 048-013. Last updated: Januar 2024. https:\/\/register.awmf.org\/de\/leitlinien\/detail\/048-013. Last accessed: 5 October 2024\u200b"},{"key":"3533_CR10","unstructured":"European committee on antimicrobial susceptibility testing (EUCAST) (2010) Amoxicillin: rationale for the EUCAST clinical breakpoints. Version 1.0. Last updated: 22 November 2010. https:\/\/www.eucast.org\/fileadmin\/src\/media\/PDFs\/EUCAST_files\/Rationale_documents\/Amoxicillin_rationale_Nov2010_v_1.0.pdf. Last Accessed: 19 September 2024"},{"key":"3533_CR11","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1007\/s40121-021-00541-4","volume":"10","author":"JC Abdul-Mutakabbir","year":"2021","unstructured":"Abdul-Mutakabbir JC, Griffith NC, Shields RK et al (2021) Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious Diseases Pharmacists. Infect Dis Ther 10:2177\u20132202. https:\/\/doi.org\/10.1007\/s40121-021-00541-4","journal-title":"Infect Dis Ther"},{"key":"3533_CR12","doi-asserted-by":"publisher","unstructured":"Al-Qurashi E, Elbnna K, Ahmad I, Abulreesh HH (2022) Antibiotic resistance in Proteus mirabilis: mechanism, status, and public health significance. J Pure Appl Microbiol. 2022;16(3):1550-1561. https:\/\/doi.org\/10.22207\/JPAM.16.3.59","DOI":"10.22207\/JPAM.16.3.59"},{"key":"3533_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.00044","author":"K AnnavajhalaMedini","year":"2019","unstructured":"AnnavajhalaMedini K, Gomez-Simmonds A, Uhlemann A-C (2019) Multidrug-resistant Enterobacter cloacae complex emerging as a global, diversifying threat. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2019.00044","journal-title":"Front Microbiol"},{"key":"3533_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"Antimicrobial Resistance Collaborators","year":"2022","unstructured":"Antimicrobial Resistance Collaborators (2022) Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399:629\u2013655. https:\/\/doi.org\/10.1016\/S0140-6736(21)02724-0","journal-title":"Lancet"},{"key":"3533_CR15","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03171-y","author":"LJ Bindel","year":"2024","unstructured":"Bindel LJ, Seifert R (2024) Costs are a major driver of antibacterial drug prescriptions in Germany: market analysis from 1985 to 2022. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03171-y","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"3533_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03288-0","author":"LJ Bindel","year":"2024","unstructured":"Bindel LJ, Seifert R (2024) DDD-costs have a strong influence on antibacterial drug prescription in Germany: a differentiated correlation analysis from 1985 to 2022. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03288-0","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"key":"3533_CR17","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-024-03435-7","author":"LJ Bindel","year":"2024","unstructured":"Bindel LJ, Seifert R (2024) Daily defined dose-costs have a stronger influence on antibacterial drug prescriptions in Germany than bacterial resistance: economic factors are more important than scientific evidence. Naunyn-Schmiedeberg\u2019s Arch Pharmacol. https:\/\/doi.org\/10.1007\/s00210-024-03435-7","journal-title":"Naunyn-Schmiedeberg's Arch Pharmacol"},{"issue":"11","key":"3533_CR18","doi-asserted-by":"publisher","first-page":"2472","DOI":"10.1093\/jac\/dkq336","volume":"65","author":"CC Butler","year":"2010","unstructured":"Butler CC, Hood K, Kelly MJ, Goossens H, Verheij T, Little P, Melbye H, Torres A, M\u00f6lstad S, Godycki-Cwirko M, Almirall J, Blasi F, Schaberg T, Edwards P, Rautakorpi UM, Hupkova H, Wood J, Nuttall J, Coenen S (2010) Treatment of acute cough\/lower respiratory tract infection by antibiotic class and associated outcomes: a 13 European country observational study in primary care. J Antimicrob Chemother. 65(11):2472\u20138. https:\/\/doi.org\/10.1093\/jac\/dkq336","journal-title":"J Antimicrob Chemother."},{"issue":"1","key":"3533_CR19","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s43856-023-00289-7","volume":"3","author":"SS Cherny","year":"2023","unstructured":"Cherny SS, Chowers M, Obolski U (2023) Bayesian network modeling of patterns of antibiotic cross-resistance by bacterial sample source. Commun Med (Lond) 3(1):61. https:\/\/doi.org\/10.1038\/s43856-023-00289-7","journal-title":"Commun Med (Lond)"},{"issue":"8025","key":"3533_CR20","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/d41586-024-02601-4","volume":"632","author":"A Dance","year":"2024","unstructured":"Dance A (2024) Five ways science is tackling the antibiotic resistance crisis. Nature 632(8025):494\u2013496. https:\/\/doi.org\/10.1038\/d41586-024-02601-4","journal-title":"Nature"},{"key":"3533_CR21","doi-asserted-by":"publisher","first-page":"3948","DOI":"10.1093\/eurheartj\/ehad193","volume":"44","author":"V Delgado","year":"2023","unstructured":"Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, Caselli S, Doenst T, Ederhy S, Erba PA, Foldager D, Fosb\u00f8l EL, Kovac J, Mestres CA, Miller OI, Miro JM, Pazdernik M, Pizzi MN, Quintana E, Rasmussen TB, Risti\u0107 AD, Rod\u00e9s-Cabau J, Sionis A, Z\u00fchlke LJ, Borger MA et al (2023) 2023 ESC Guidelines for the management of endocarditis: developed by the task force on the management of endocarditis of the European Society of Cardiology (ESC) endorsed by the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Nuclear Medicine (EANM). Eur Heart J 44:3948\u20134042. https:\/\/doi.org\/10.1093\/eurheartj\/ehad193","journal-title":"Eur Heart J"},{"key":"3533_CR22","unstructured":"European Centre for Disease Prevention and Control (ECDC) (2023) Antimicrobial resistance in the EU\/EEA (EARS-Net) - Annual Epidemiological Report 2022. Stockholm"},{"key":"3533_CR23","doi-asserted-by":"crossref","unstructured":"Ewig S, Kolditz M, Pletz M, Altiner A, Albrich W, Droemann D, Flick H, Gatermann S, Kr\u00fcger S, Nehls W, Panning M, Rademacher J, Rohde G, Rupp J, Schaaf B, Heppner HJ, Krause R, Ott S, Welte T, Witzenrath M. (2021). Behandlung von erwachsenen Patienten mit ambulant erworbener Pneumonie \u2013 Update 2021. S3-Leitlinie der Deutschen Gesellschaft f\u00fcr Pneumologie und Beatmungsmedizin (DGP), AWMF-Registernummer 020-020. Last updated: April 30, 2021. https:\/\/register.awmf.org\/assets\/guidelines\/020-020l_S3_Behandlung-von-erwachsenen-Patienten-mit-ambulant-erworbener-Pneumonie__2021-05.pdf. Last Accessed: 19 September 2024","DOI":"10.1055\/a-1497-0693"},{"key":"3533_CR24","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3389\/fmicb.2020.00256","volume":"11","author":"D Girlich","year":"2020","unstructured":"Girlich D, Bonnin RA, Dortet L, Naas T (2020) Genetics of acquired antibiotic resistance genes in Proteus spp. Front Microbiol. 11:256. https:\/\/doi.org\/10.3389\/fmicb.2020.00256","journal-title":"Front Microbiol."},{"key":"3533_CR25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12941-024-00728-w","volume":"23","author":"L Guan","year":"2024","unstructured":"Guan L, Beig M, Wang L, Navidifar T, Moradi S, MotallebiTabaei F, Teymouri Z, AbediMoghadam M, Sedighi M (2024) Global status of antimicrobial resistance in clinical Enterococcus faecalis isolates: systematic review and meta-analysis. Annals Clin Microbiol Antimicrob 23:80. https:\/\/doi.org\/10.1186\/s12941-024-00728-w","journal-title":"Annals Clin Microbiol Antimicrob"},{"issue":"11","key":"3533_CR26","first-page":"832","volume":"13","author":"S Japoni","year":"2011","unstructured":"Japoni S, Farshad S, Abdi Ali A, Japoni A (2011) Antibacterial susceptibility patterns and cross-resistance of acinetobacter, isolated from hospitalized patients, southern Iran. Iran Red Crescent Med J 13(11):832\u20136","journal-title":"Iran Red Crescent Med J"},{"key":"3533_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13756-018-0362-9","volume":"7","author":"U Koppe","year":"2018","unstructured":"Koppe U, von Laer A, Kroll LE, Noll I, Feig M, Schneider M, Claus H, Eckmanns T, Abu SM (2018) Carbapenem non-susceptibility of Klebsiella pneumoniae isolates in hospitals from 2011 to 2016, data from the German Antimicrobial Resistance Surveillance (ARS). Antimicrob Resist Infect Control. 7:71. https:\/\/doi.org\/10.1186\/s13756-018-0362-9","journal-title":"Antimicrob Resist Infect Control."},{"key":"3533_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ijid.2016.07.006","volume":"50","author":"H Liu","year":"2016","unstructured":"Liu H, Zhu J, Qiwen H, Rao X (2016) Morganella morganii, a non-negligent opportunistic pathogen. Int J Infect Dis 50:10\u201317. https:\/\/doi.org\/10.1016\/j.ijid.2016.07.006","journal-title":"Int J Infect Dis"},{"issue":"4","key":"3533_CR29","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1111\/eva.12903","volume":"13","author":"NA Lozano-Huntelman","year":"2020","unstructured":"Lozano-Huntelman NA, Singh N, Valencia A, Mira P, Sakayan M, Boucher I, Tang S, Brennan K, Gianvecchio C, Fitz-Gibbon S, Yeh P (2020) Evolution of antibiotic cross-resistance and collateral sensitivity in Staphylococcus epidermidis using the mutant prevention concentration and the mutant selection window. Evol Appl 13(4):808\u2013823. https:\/\/doi.org\/10.1111\/eva.12903","journal-title":"Evol Appl"},{"key":"3533_CR30","doi-asserted-by":"publisher","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2021) Arzneiverordnungs-Report 2021. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-63825-5","DOI":"10.1007\/978-3-662-63825-5"},{"key":"3533_CR31","doi-asserted-by":"publisher","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2023) Arzneiverordnungs-Report 2022. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-66303-5","DOI":"10.1007\/978-3-662-66303-5"},{"key":"3533_CR32","doi-asserted-by":"publisher","unstructured":"Ludwig W, M\u00fchlbauer M, Seifert R (2024) Arzneiverordnungs-Report 2023. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-68371-2","DOI":"10.1007\/978-3-662-68371-2"},{"key":"3533_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s13756-019-0594-3","author":"R Markwart","year":"2019","unstructured":"Markwart R, Willrich N, Haller S, Noll I, Koppe U, Werner G, Eckmanns T, Reuss A (2019) The rise in vancomycin-resistant Enterococcus faecium in Germany: data from the German Antimicrobial Resistance Surveillance (ARS). Antimicrob Resist Infect Control. https:\/\/doi.org\/10.1186\/s13756-019-0594-3","journal-title":"Antimicrob Resist Infect Control"},{"key":"3533_CR34","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"Mukaka MM (2012) Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24:69\u201371","journal-title":"Malawi Med J"},{"key":"3533_CR35","unstructured":"O\u2019Neill J (2014) Antimicrobial resistance: tackling a crisis for the health and wealth of nations. Review on Antimicrobial Resistance. https:\/\/wellcomecollection.org\/works\/rdpck35v"},{"key":"3533_CR36","unstructured":"Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e.V (PEG), Bundesamt f\u00fcr Verbraucherschutz und Lebensmittelsicherheit. (2016) GERMAP 2015 \u2013 Bericht \u00fcber den Antibiotikaverbrauch und die Verbreitung von Antibiotikaresistenzen in der Human- und Veterin\u00e4rmedizin in Deutschland. Antiinfectives Intelligence. ISBN 978-3-9818383-0-5"},{"key":"3533_CR37","unstructured":"Paul-Ehrlich-Gesellschaft f\u00fcr Chemotherapie e.V. (PEG) (2019) Kalkulierte parenterale Initaltherapie bakterieller Erkrankungen bei Erwachsenen \u2013 Update 2018. PEG S2k Leitlinie. AWMF Registernummer 082-006. 2. Aktualisierte Version, last updated 25. July 2019. https:\/\/www.p-e-g.org\/files\/content\/Service\/Empfehlungen-Leitlinien\/PEG-S2k-Leitlinie-Update-2018.pdf. Last Accessed: 19 September 2024"},{"key":"3533_CR38","unstructured":"Robert Koch Institut (RKI) (2024) ARS \u2013 Antibiotika Resistenz Surveillance. Datenbank. Resistenzstatistik. Accessed: 2024, 10.03. https:\/\/ars.rki.de\/"},{"issue":"20","key":"3533_CR39","doi-asserted-by":"publisher","first-page":"2200672","DOI":"10.2807\/1560-7917.ES.2023.28.20.2200672","volume":"28","author":"M R\u00f6denbeck","year":"2023","unstructured":"R\u00f6denbeck M, Ayobami O, Eckmanns T, Pletz MW, Bleidorn J, Markwart R (2023) Clinical epidemiology and case fatality due to antimicrobial resistance in Germany: a systematic review and meta-analysis, 1 January 2010 to 31 December 2021. Euro Surveill. 28(20):2200672. https:\/\/doi.org\/10.2807\/1560-7917.ES.2023.28.20.2200672","journal-title":"Euro Surveill."},{"key":"3533_CR40","doi-asserted-by":"publisher","unstructured":"Rolff J, Bonhoeffer S, Kloft C, Leistner R, Regoes R, Hochberg ME (2024) Forecasting antimicrobial resistance evolution. Trends Microbiol. 2024;32(8):736-745. https:\/\/doi.org\/10.1016\/j.tim.2023.12.009","DOI":"10.1016\/j.tim.2023.12.009"},{"key":"3533_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.3201\/eid1901.120310","volume":"1","author":"GV Sanchez","year":"2013","unstructured":"Sanchez GV, Master RN, Clark RB, Fyyaz M, Duvvuri P, Ekta G, Bordon J (2013) Klebsiella pneumoniae antimicrobial drug resistance, United States, 1998\u20132010. Emerg Infect Dis. 1:133\u20136. https:\/\/doi.org\/10.3201\/eid1901.120310","journal-title":"Emerg Infect Dis."},{"key":"3533_CR42","doi-asserted-by":"publisher","unstructured":"Schwabe U, Ludwig W (2020) Arzneiverordnungs-Report 2020. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-62168-4","DOI":"10.1007\/978-3-662-62168-4"},{"key":"3533_CR43","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2010a) Arzneiverordnungs-Report 2008. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-540-69219-5","DOI":"10.1007\/978-3-540-69219-5"},{"key":"3533_CR44","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2010b) Arzneiverordnungs-Report 2009. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-01080-4","DOI":"10.1007\/978-3-642-01080-4"},{"key":"3533_CR45","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2011a) Arzneiverordnungs-Report 2010. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-13380-0","DOI":"10.1007\/978-3-642-13380-0"},{"key":"3533_CR46","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2011b) Arzneiverordnungs-Report 2011. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-21992-4","DOI":"10.1007\/978-3-642-21992-4"},{"key":"3533_CR47","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2012) Arzneiverordnungs-Report 2012. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-29242-2","DOI":"10.1007\/978-3-642-29242-2"},{"key":"3533_CR48","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2013) Arzneiverordnungs-Report 2013. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-642-37124-0","DOI":"10.1007\/978-3-642-37124-0"},{"key":"3533_CR49","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2014) Arzneiverordnungs-Report 2014. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-43487-1","DOI":"10.1007\/978-3-662-43487-1"},{"key":"3533_CR50","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2015) Arzneiverordnungs-Report 2015. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-47186-9","DOI":"10.1007\/978-3-662-47186-9"},{"key":"3533_CR51","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2016) Arzneiverordnungs-Report 2016. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-50351-5","DOI":"10.1007\/978-3-662-50351-5"},{"key":"3533_CR52","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D (2017) Arzneiverordnungs-Report 2017. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-54630-7","DOI":"10.1007\/978-3-662-54630-7"},{"key":"3533_CR53","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2018) Arzneiverordnungs-Report 2018. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-57386-0","DOI":"10.1007\/978-3-662-57386-0"},{"key":"3533_CR54","doi-asserted-by":"publisher","unstructured":"Schwabe U, Paffrath D, Ludwig W, Klauber J (2019) Arzneiverordnungs-Report 2019. 1. (Berlin, Heidelberg: Springer). https:\/\/doi.org\/10.1007\/978-3-662-59046-1","DOI":"10.1007\/978-3-662-59046-1"},{"key":"3533_CR55","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1038\/s41467-023-36252-2","volume":"14","author":"L Semenec","year":"2023","unstructured":"Semenec L, Cain AK, Dawson CJ et al (2023) Cross-protection and cross-feeding between Klebsiella pneumoniae and Acinetobacter baumannii promotes their co-existence. Nat Commun 14:702. https:\/\/doi.org\/10.1038\/s41467-023-36252-2","journal-title":"Nat Commun"},{"key":"3533_CR56","doi-asserted-by":"publisher","unstructured":"Werner G, Neumann B, Weber RE, Kresken M, Wendt C, Bender JK; VRE study group (2020) Thirty years of VRE in Germany - \"expect the unexpected\": the view from the National Reference Centre for Staphylococci and Enterococci. Drug Resist Updat. 53:100732. https:\/\/doi.org\/10.1016\/j.drup.2020.100732","DOI":"10.1016\/j.drup.2020.100732"},{"key":"3533_CR57","unstructured":"World Health Organization (WHO) (2022) Report signals increasing resistance to antibiotics in bacterial infections in humans and need for better data. Accessed: 13 September 2024. https:\/\/www.who.int\/news\/item\/09-12-2022-report-signals-increasing-resistance-to-antibiotics-in-bacterial-infections-in-humans-and-need-for-better-data"},{"key":"3533_CR58","doi-asserted-by":"publisher","first-page":"10","DOI":"10.38105\/spr.7bhjorymhn","volume":"1","author":"EH Yee","year":"2020","unstructured":"Yee EH, Cheng SS, Knappe GA, Moomau CA (2020) Antibiotic resistance: how to prevent the next public health emergency. MIT Sci Policy Rev 1:10. https:\/\/doi.org\/10.38105\/spr.7bhjorymhn","journal-title":"MIT Sci Policy Rev"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03533-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T02:02:16Z","timestamp":1744164136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03533-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3533"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03533-6","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"20 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was conducted according to the guidelines of good scientific practice of the Hannover Medical School () and officially registered as a doctoral thesis project for Lilly Josephine Bindel. The Hannover Medical School follows the guidelines of the German Research Foundation (Deutsche Forschungsgemeinschaft, DFG).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable because publicly available information is used as a data source.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"R.S. in the Editor-in-Chief of Naunyn-Schmiedebergs Arch Pharmacol and follows the editorial guidelines of editors acting as authors ().","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}